{"id":"W2489765770","doi":"10.1200/jco.2013.31.15_suppl.8034","title":"Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Pemetrexed; Internal medicine; Clinical endpoint; Lung cancer; Placebo; Population; non-small cell lung cancer (NSCLC); Bevacizumab; Intention-to-treat analysis; Phases of clinical research; Hazard ratio; Surgery; Gastroenterology; Adverse effect; Oncology; Randomized controlled trial; Chemotherapy; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001167574,0.0004021366,0.003655201,0.0004721108,0.00004483683,0.0000121757,0.0002619859,0.0003217318,0.0005111856],"category_scores_gemma":[0.0005112133,0.0002623138,0.0005840497,0.0004598731,0.000241309,0.0002419164,0.00006948055,0.0008572788,0.000002821323],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008114474,"about_ca_system_score_gemma":0.00166885,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00134066,"about_ca_topic_score_gemma":0.003400065,"domain_scores_codex":[0.9945019,0.0003711838,0.003632826,0.0004186804,0.0006578291,0.0004175579],"domain_scores_gemma":[0.9920316,0.002092368,0.003506539,0.0003887647,0.001588208,0.0003925331],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8444742,0.01947092,0.1187628,0.0001932833,0.002745209,0.0001119183,0.003227934,0.0009099035,0.00002527082,4.330451e-7,0.0002604459,0.009817732],"study_design_scores_gemma":[0.9350902,0.02453738,0.03029684,0.000579378,0.00395375,0.000004409144,0.001698816,0.003359121,0.0001108029,0.000001101816,0.0001536689,0.0002145438],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894295,0.001080648,0.0003808584,0.0006990236,0.0009156977,0.007169683,0.00002183028,0.0000101894,0.0002926198],"genre_scores_gemma":[0.9955795,0.0004867119,0.002679501,0.0002282514,0.000220507,0.0005132188,0.00001776489,0.00005776148,0.000216739],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09061602,"threshold_uncertainty_score":0.9999829,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03439827634792551,"score_gpt":0.4187136529175101,"score_spread":0.3843153765695846,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}